ストックスクリーナーアプリを入手
0.43
19.66%
-0.1052
Estrella Immunopharma Inc (ESLA) 最新ニュース
A director receives 2,037 shares instead of cash at Hyperliquid Strategies (PURR). - Stock Titan
Stock replaces cash pay for a Hyperliquid Strategies (PURR) director, who acquires 3,056 shares. - Stock Titan
Shares replace cash pay for Hyperliquid Strategies (PURR) director in 1,358-share award - Stock Titan
A 15,000-share sale is proposed by Cloudastructure (CSAI) founder Sheldon Richard Bentley. - Stock Titan
ESLA 10-K/A & SEC Filings - Yahoo! Finance Canada
A director received 21,154 stock units at WRAP Technologies (WRAP); 13,750 vested on October 1. - Stock Titan
Director John Burgess exercises 5,000 Taylor Devices (TAYD) options at $13.80 each. - Stock Titan
After a 213-share grant, ChoiceOne (COFS) director Curt E. Coulter holds 11,365 shares directly. - Stock Titan
AT&T (T) CFO acquires 1,836 stock units through payroll deductions and partial company matching. - Stock Titan
Three monthly payments go to ARMOUR's preferred shareholders through December. - Stock Titan
Across three days, DSS sold 906 Impact Biomedical (IBO) shares at prices from $0.55 to $7.0587. - Stock Titan
Estrella Immunopharma Warrant (ESLAW) Trades Flat at $0.07 as Range Holds TightChaikin Flow - dars.gov.et
Estrella Immunopharma Warrant (ESLAW) Trades Flat at $0.07 as Range Holds TightAI Trade Signals - dars.gov.et
Estrella Immunopharma Warrant (ESLAW) Trades Flat at $0.07 as Range Holds TightHigh Dividend Factor - dars.gov.et
Rule 10b5-1 stock sale by F5 (FFIV) marketing chief - Stock Titan
Estrella Immunopharma Faces Nasdaq Listing Compliance Challenge - TipRanks
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Intercontinental Exchange (NYSE: ICE) officer sells 5,000 shares under trading plan - Stock Titan
MiNK Therapeutics (INKT) insider reports stock trades - Stock Titan
QT Imaging (QTI) awards its CEO 484K RSUs that vest through 2030, with all shares accelerating if the company undergoes a change of control. - Stock Titan
Greif shareholders will receive $0.62 or $0.93 per share on Oct. 1 - Stock Titan
Apollo Commercial (NYSE: ARI) director plans 960-share family sale - Stock Titan
Estrella Immunopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ARMISTICE CAPITAL, LLC Reduces Stake in Estrella Immunopharma Inc (ESLA) by Nearly Half - GuruFocus
PriceSmart (NASDAQ: PSMT) executive sells 338 shares at $177.87 - Stock Titan
Estrella Immunopharma (ESLA) Holds Ground at $0.72 as Immunotherapy Pipeline Takes Center StageLong Short Pair - vinanet.vn
Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella Immunopharma (ESLA) Holds Ground at $0.72 as Immunotherapy Pipeline Takes Center StageLow Risk Entry Stocks - dars.gov.et
Estrella Immunopharma (ESLA) Holds at $0.72 as Support Firms in Quiet Micro-Cap SessionIchimoku TK Cross - vinanet.vn
ESLAW Warrants Hold Flat at $0.07 as Support and Resistance AlignInstitutional Buy Signals - vinanet.vn
ESLAW Warrants Hold Flat at $0.07 as Support and Resistance AlignTriangle Correction - siam.in
ESLAW Warrants Hold Flat at $0.07 as Support and Resistance AlignScalping Stock Signals - dars.gov.et
Estrella Immunopharma (ESLA) Holds at $0.72 as Support Firms in Quiet Micro-Cap SessionFactor Rotation - dars.gov.et
Estrella Immunopharma Inc. (NASDAQ: ESLA) Share Price, ESLA Stock News, ESLA Share Price & Updates - kalkine.com.au
ESLAW Warrant Holds at $0.07 as Estrella Immunopharma Trades FlatSystematic Flow - vinanet.vn
Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake - Stock Titan
ESLAW Warrant Holds at $0.07 as Estrella Immunopharma Trades FlatPost-Earnings Moves - dars.gov.et
ESLAW Warrant Holds at $0.07 as Estrella Immunopharma Trades FlatFibonacci Fan - dars.gov.et
ESLAW Warrant Holds at $0.07 as Estrella Immunopharma Trades FlatSingle Stock ETF - dars.gov.et
ESLAW Warrant Holds at $0.07 as Estrella Immunopharma Trades FlatLow Risk Entry Stocks - dars.gov.et
Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary - TradingView
Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace
Estrella adds fourth site to EB103 lymphoma trial - Investing.com
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - Yahoo Finance
Estrella Immunopharma Inc (ESLA) Stock News Today - TradingKey
Estrella Immunopharma (ESLA) Stock Price, News & Analysis - MarketBeat
Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
4.22%
大文字化:
|
ボリューム (24 時間):